Financial Engines Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Financial Engines Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$277K	Sell	621 -32	-5%	-$14.9K	﹤0.01%	479
2025 Q4	$296K	Buy	653 +25	+4%	+$10.8K	﹤0.01%	470
2025 Q3	$246K	Buy	628 +3	+0.5%	+$1.25K	﹤0.01%	500
2025 Q2	$278K	Buy	+625	New	+$288K	﹤0.01%	460
2020 Q3	–	Sell	-827	Closed	-$240K	–	257
2020 Q2	$240K	Buy	+827	New	+$224K	﹤0.01%	177
2018 Q1	–	Sell	-12	Closed	-$2K	–	233
2017 Q4	$2K	Buy	+12	New	+$1.78K	﹤0.01%	159

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Financial Engines Advisors's VRTX Position: Q1 2026 in Review

Financial Engines Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 4.9% in Q1 2026, selling an estimated $14.9K and leaving 621 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #479.

Financial Engines Advisors first reported a position in VRTX in Q4 2017 and has held it in 6 quarters since. The position peaked at $296K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Financial Engines Advisors held 621 shares of Vertex Pharmaceuticals worth $277K as of Q1 2026.
Financial Engines Advisors sold 32 Vertex Pharmaceuticals shares in Q1 2026, an estimated $14.9K.
Vertex Pharmaceuticals made up ﹤0.01% of Financial Engines Advisors's portfolio in Q1 2026, its #479 holding.
Financial Engines Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
Financial Engines Advisors's Vertex Pharmaceuticals position peaked at $296K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Financial Engines Advisors's 13F filing for Q1 2026, filed 14 May 2026.